HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study.
暂无分享,去创建一个
S. Martino | R. Elledge | D. Allred | G. Clark | P. Ravdin | C. Osborne | S. Green | D. Ciocca | R. Pugh | J. O'Sullivan | J. Hill | Julian B. Hill | Mississippi Tupelo | Oncology | Janet O 'sullivan | C. Southwest | R P North | Mississippi Hematology | J. Hill | D. Ciocca | Sylvan B. Green | R. Pugh | Janet O'Sullivan
[1] R. Gelman,et al. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] C. Osborne,et al. bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] A. Bianco,et al. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] D. Stern,et al. Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours. , 1996, British Journal of Cancer.
[5] I. Ellis,et al. Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. , 1995, British Journal of Cancer.
[6] M. Sliwkowski,et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. , 1995, Oncogene.
[7] J. Foekens,et al. Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. , 1995, Gene.
[8] V. Chinchilli,et al. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] M. Fernö,et al. ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. , 1994, Cancer letters.
[10] D. Slamon,et al. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. , 1994, Cancer research.
[11] T. Singleton,et al. Stability of HER-2/neu expression over time and at multiple metastatic sites. , 1993, Journal of the National Cancer Institute.
[12] W. McGuire,et al. Correlation of HER-2/neu amplification with expression and with other prognostic factors in 1103 breast cancers. , 1992, Journal of the National Cancer Institute.
[13] W. McGuire,et al. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] B. Gusterson,et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] C. Osborne,et al. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] J. Cairns,et al. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. , 1992, British Journal of Cancer.
[17] M. Gerretsen,et al. Br. J. Cancer , 1993 .